Expedited development and approval pathways at the Food and Drug Administration (FDA) such as Priority review, Fast Track Designation, Breakthrough Designation, and Accelerated Approval are programs available to drug sponsors that aim to incentivize and expedite the delivery of drugs to patients in need. In addition, other incentive programs such as Orphan Drug Designation (ODD), Qualified Infectious Disease Product Designation (QIDP), and Rare Pediatric Disease Designation (RPDD) are available to drug sponsors to help motivate development of drugs that may have lower economic incentive for commercialization. These programs have been largely effective, and many new innovative drugs since 2010 have accessed these programs. This Perspective highlights how these programs have been used in recent FDA drug approvals and discusses future ways sponsors and regulatory agencies may further enable development of these innovative drugs in the most expeditious fashion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.3c02165 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlabelled: Early phase dose-finding (EPDF) trials are key in the development of novel therapies, with their findings directly informing subsequent clinical development phases and providing valuable insights for reverse translation. Comprehensive and transparent reporting of these studies is critical for their accurate and critical interpretation, which may improve and expedite therapeutic development. However, quality of reporting of design characteristics and results from EPDF trials is often variable and incomplete.
View Article and Find Full Text PDFDiabetes mellitus and peripheral artery disease.
Diabetol Int
January 2025
Department of Laboratory Medicine, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita City, Osaka 565-0871 Japan.
Atherosclerotic peripheral artery disease (PAD), that is, arteriosclerosis obliterans, is pathologically rooted in atherosclerosis, similar to other cardiovascular diseases. In addition to smoking, hypertension, and dyslipidemia, diabetes mellitus is a major risk factor. People with diabetes mellitus have an elevated risk of developing PAD.
View Article and Find Full Text PDFRealizing a 3C Fast-Charging Practical Sodium Pouch Cell.
Angew Chem Int Ed Engl
January 2025
Beihang University, 37 Xue Yuan Road, Hai Dian District, 100191, Beijing, CHINA.
Sodium-ion batteries (SIBs), endowed with relatively small Stokes radius and low desolvation energy for Na+, are reckoned as a promising candidate for fast-charging endeavors. However, the C-rate charging capability of practical energy-dense sodium-ion pouch cells is currently limited to ≤1C, due to the high propensity for detrimental metallic Na plating on the hard carbon (HC) anode at elevated rates. Here, an ampere-hour-level sodium-ion pouch cell capable of 3C charging is successfully developed via phosphorus (P)-sulfur (S) interphase chemistry.
View Article and Find Full Text PDFLeveraging Network Target Theory for Efficient Prediction of Drug-Disease Interactions: A Transfer Learning Approach.
Adv Sci (Weinh)
January 2025
Department of Molecular Pharmacology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300060, China.
Efficient virtual screening methods can expedite drug discovery and facilitate the development of innovative therapeutics. This study presents a novel transfer learning model based on network target theory, integrating deep learning techniques with diverse biological molecular networks to predict drug-disease interactions. By incorporating network techniques that leverage vast existing knowledge, the approach enables the extraction of more precise and informative drug features, resulting in the identification of 88,161 drug-disease interactions involving 7,940 drugs and 2,986 diseases.
View Article and Find Full Text PDFDevelopment of a bio-inspired wound model for debridement training.
In Vitro Model
June 2024
Department of Pharmacy, University of Huddersfield, Queensgate, Huddersfield, HD1 3DH UK.
Unlabelled: Wound debridement is commonplace in expediting wound healing in the clinic. Despite this, there are limited resources available for simulation training for practitioners prior to facing real-life patients. Typically, citrus peels or porcine skin are employed in a vain attempt to improve debridement proficiency, yet these fail to provide a realistic experience of the textures and consistencies of wounds.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!